HopeStage
Back to all studies
CompletedNCT01041092

Raloxifene added to antipsychotic treatment for schizophrenia symptoms

About this titleRead the official source — NCT01041092

This study evaluated the safety and effectiveness of raloxifene for people with schizophrenia.

Medication studyAges 40+Spain
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of raloxifene for people with schizophrenia.

Who was this study for?

Listed age limits: from 40 years.

Listed locations
Esplugues de LlobregatSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJune 2004
Recruitment status
Completed
Enrollment listed in the registry
34
Sponsor
Fundació Sant Joan de Déu
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Spain
Age range
Over 40 Years
Official registry ID
NCT01041092
Official title
Show the full official title

Double Blind, Placebo-controlled Study of Efficacy, Safety and Tolerance of Raloxifene as an Adjuvant Treatment for Negative Symptoms of Schizophrenia in Postmenopausal Women

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Esplugues de Llobregat

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of raloxifene for people with schizophrenia.

Who is behind this study?

The study sponsor is Fundació Sant Joan de Déu.

Did this study involve medication?

Yes. The study involved medication, including raloxifene.

Who was this study for?

Listed age limits: from 40 years.

Want to explore more studies?

Explore studies